Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Medicago BioSolutions AB
AB
Active
Org 5594067562
Danmarks-Berga 13
Manufacture of other organic basic chemicals · NACE 2014
Est. 2022
12 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2024
SEK 50,7M
+7% vs 2023
EBITDA margin
30.1%
-3% vs 2023
Equity ratio
62.0%
Financial strength
Net profit 2024
SEK 11,3M
+22% vs 2023
EBITDA — year on year
SEK millions
20M
15M
10M
5M
0M
16M
2023
15M
-6%
2024
Key figures
Annual report 2024
Revenue
SEK 50,7M
+7%
EBITDA
SEK 15,3M
-3%
Net profit
SEK 11,3M
+22%
Total assets
SEK 29,7M
+57%
Equity
SEK 18,4M
+98%
Employees
12
—
Company information
Legal name
Medicago BioSolutions AB
Org number
5594067562
Legal form
Aktiebolag
NACE code
2014 · Manufacture of other organic basic chemicals
Founded
18 november 2022
Share capital
SEK 25 000
Employees
12 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bedriva produktion av buffertar, reagenser och proteiner för laboratoriebruk inom bioteknik och life science.
Contact
Address
Danmarks-Berga 13
Email
emil.linde@medicagogroup.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Manufacture of other organic basic chemicals
Companies in Uppsala
All Sweden companies
Revenue
SEK millions
0M
15M
29M
44M
59M
47M
2023
51M
2024
EBITDA
SEK millions
0M
5M
9M
14M
18M
16M
2023
15M
2024
Income statement
SEK thousands
Item
2023
2024
Revenue
47 235
50 712
Staff expenses
—
—
EBITDA
15 734
15 272
Depreciation & amort.
−43
−126
EBIT
15 691
15 146
Net financials
39
346
Profit before tax
11 675
14 291
Tax
−2 404
−2 957
Net profit
9 271
11 334
Balance sheet
SEK thousands
Item
2023
2024
Total assets
18 969
29 719
Equity
9 296
18 430
Long-term debt
0
0
Short-term debt
5 487
6 957
Total debt
5 487
6 957
Financial ratios
5-year trend
EBITDA margin
30.1%
This company
15.8%
Market median
+91% vs market
2023
2024
Equity ratio
62.0%
This company
38.2%
Market median
+62% vs market
2023
2024
Return on equity
61.5%
This company
18.4%
Market median
+234% vs market
2023
2024
Net profit margin
22.3%
This company
8.1%
Market median
+175% vs market
2023
2024
Asset turnover
1.71×
This company
1.12×
Market median
+53% vs market
2023
2024
Debt / equity
0.61×
This company
0.62×
Market median
+2% vs market
2023
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2022-11-01 – 2023-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Current (2)
EL
Emil Linde
Chief Executive Officer
Chief Executive Officer
2022
KJ
Kurt Johan Rikard Rönnblom
Audit
Audit
2022
Board of directors
Non-executive oversight
Name
Role
Member since
Current (2)
AE
Anton Edling
Chairman
2022
JA
Jan Anders Ragnar Henriksson
Deputy Board Member
2022
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Medicago Aktiebolag
Company
100%
100%
2023
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
Medicago Aktiebolag
Medicago BioSolutions AB
(this company)
Board network connections
Board members of Medicago BioSolutions AB also hold positions in
0
other companies.
Person
Role here
Other companies
Emil Linde
Chief Executive Officer
0 companies
Kurt Johan Rikard Rönnblom
Audit
0 companies
Anton Edling
Chairman
0 companies
Jan Anders Ragnar Henriksson
Deputy Board Member
0 companies